Research progress on ketamine for the treatment of substance use disorders
Journal Title: Chinese Journal of Nervous and Mental Diseases - Year 2024, Vol 50, Issue 10
Abstract
Substance use disorder is a complex health condition characterized by excessive dependence and abuse of psychoactive substances. Current treatments are few and generally ineffective, and new treatment methods are urgently needed. In recent years, ketamine has been found to be effective in the treatment of substance use disorders in controlling relapse rates and reducing withdrawal reactions in clinical studies. Basic research has shown that ketamine has a therapeutic effect by altering neuroplasticity and modulating neurofunctional networks. However, the use of ketamine may lead to side effects such as increased blood pressure and psychiatric symptoms, and potential addiction. But current clinical studies are optimistic about its safety. As a fast-acting drug with a novel mechanism of action, ketamine needs to be studied in depth to explore its benefits and risks, thereby providing a safe and effective new method for the treatment of substance use disorders.
Authors and Affiliations
Tinghan FU, Huanzhong LIU, Kai. ZHANG
Keywords
Related Articles
- EP ID EP759181
- DOI 10.3969/j.issn.1002-0152.2024.10.011
- Views 39
- Downloads 0
Research progress on the study of aceruloplasminemia
Aceruloplasminemia (ACP) is a rare, adult-onset autosomal recessive disorder characterized by ceruloplasmin (CP) deficiency and iron metabolism disorders, with typical clinical manifestations of the triad of "neurologica...
Analysis of risk factors of massive cerebral infarction after craniocerebral injury in children with acute subdural hematoma.
[Objective] To analyze and compare the clinical manifestations and imaging features of children with secondary massive cerebral infarction after acute subdural hematoma (ASDH), and to evaluate its potential risk factors...
A case of adult-type Sifrim-Hitz-Weiss syndrome
A case of Sifrim-Hitz-Weiss syndrome (Sifrim-Hitz-Weiss syndrome, SIHIWES) is presented. The patient was a 35-year-old male with cryptorchidism, growth retardation, skeletal malformations, muscular atrophy, a wide forehe...
Recommendations on clinical application of deutetrabenazine for treatment of tardive dyskinesia
Deutetrabenazine (DTBZ) is a selective oral small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its pharmacological action works by inhibiting VMAT2, thereby reducing the release of presynaptic dopamin...
Spinocerebellar ataxia type 2 with Parkinsonism as the main manifestation: a case report
The patient was diagnosed with “motor retardation for 3 years” in the neurology department of our hospital, accompanied by static tremors and ataxia. Physical examination showed that there was a tendency to decrease for...